Metabolic

Cagrilintide

Controlled trials

Long-acting amylin analogue, not a GLP-1.

SubQAdvancedNot approved anywhereappetite controlfat lossmetabolic health

Also known as AM833 · Cagri

At a glance

Dose summary

Typical dose2.4 mg
Range300 mcg–4.5 mg
FrequencyWeekly
Half-life~7.5 days
ScheduleOnce a week
Cycle lengthNot cycled
RouteSubQ
Experience levelAdvanced
Evidence gradeControlled trials
ApprovalNot approved anywhere
Where the dose comes fromPublished trial dosing

Reconstitution

What to draw, at the usual vial

A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5.00 mg/mL. A typical 2.4 mg dose is 0.480 mL — pull the plunger to 48 units on a U-100 syringe.

Concentration5.00 mg/mL
Draw volume0.480 mL
U-100 units48 units
Doses per vial4

Same dose, other vial sizes

VialWaterConcentrationDrawUnitsDoses
5 mg2 mL2.50 mg/mL0.960 mL96 units2
10 mg2 mL5.00 mg/mL0.480 mL48 units4

The highlighted row is the one quoted above: the smallest listed vial that holds at least four typical doses. Change any of it — a different vial, more or less water, a different dose — on the reconstitution calculator, which draws the syringe to true U-100 graduations.

Titration

Step-up ladder

This compound is escalated rather than held flat. Each step is a fixed number of weeks before the next increase — the side effects cluster in the days after a step, not at the top of the ladder.

StepWeeksDoseNote
11–4300 mcgstarting dose
25–8600 mcg
39–121.2 mg
413–162.4 mg
517–204.5 mgtrial maximum

Full ladder: 20 weeks from the starting dose to the top step.

Mechanism & evidence

What it is, and what is known

Long-acting amylin analogue, not a GLP-1. Phase 2 randomized human trials dosed 0.3 to 4.5 mg once weekly with 4-week step-ups, and it is in phase 3 combined with semaglutide as CagriSema. It is investigational and NOT approved anywhere as a standalone product. Amylin analogues act on satiety through a different receptor to GLP-1, which is the rationale for the combination, but standalone long-term data does not yet exist.

The caveat

Phase 2 complete, phase 3 running as a combination. No standalone long-term data.

Tolerability

Reported side effects

  • Nausea, generally milder than with a GLP-1 at equivalent appetite suppression
  • Constipation
  • Injection site reactions
  • Reduced appetite and early satiety

Hard stops

Do not use this if

  • Pregnancy, possible pregnancy, or breastfeeding
  • Under 18

These are flags, not a screening. They do not replace a conversation with a clinician who knows your history.

Handling

Storage

Sealed powder, refrigerated24 months
After reconstitution, refrigerated56 days

Keep it cold, keep it dark, and label the vial with the date you mixed it. Discard anything cloudy or past the window above.

Combinations

Commonly stacked with

Stacking multiplies the side-effect surface and makes it impossible to tell which compound did what. Add one thing at a time.

References

Sources

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.